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OBJECTIVES: This study compared the costs and 
the effectiveness of thyrotropin-alfa with the standard
approach (withdrawal of thyroid hormone suppression
therapy [THST]) for the detection of thyroid remnants in
the follow up of post-thyroidectomy patients maintained
on hormone suppression therapy. METHODS: Head to
head clinical trial data were combined with a retrospec-
tive analysis of medical resources and costs of both treat-
ment alternatives. Indirect costs (i.e. productivity loss)
were assessed from a separate prospective study. The
analysis was performed from a societal perspective with
a time horizon of four months, reﬂecting the time
required for the initial evaluation of disease. RESULTS:
The clinical trials showed that the use of thyrotropin-alfa
resulted in a statistically signiﬁcant avoidance of signs and
symptoms of hypothyroidism measured by the validated
Billewicz scale. A statistically signiﬁcant improved
Quality of Life on the POMS scale and on ﬁve domains
of the SF-36 scale was observed with the use of thy-
rotropin-alfa. Total medical costs related to use of thy-
rotropin-alfa are €1,723,83. No indirect costs are related
to the use of thyrotropin-alfa. The total medical costs
with the use of the thyroid hormone withdrawal period
are €854,03, while the indirect costs, caused by loss of
working hours, were assessed to be €810,00 amounting
to a total of €1,664,03. Treatment with thyrotropin-alfa
results in a net increase of €59,80. The main differences
in costs between the two treatment alternatives are deter-
mined by the acquisition costs of thyrotropin-alfa and
costs related to loss of productivity. The analysis was 
sensitive to variation in indirect costs, but robust for 
variations of other parameters. CONCLUSIONS: It can
be concluded that thyrotropin-alfa is a cost-effective
treatment compared to the method of thyroid hormone
withdrawal in the follow up of post-thyroidectomy
patients for four months in the Netherlands.
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OBJECTIVE: To determine whether improvement in
quality of life (QoL) in hypopituitary adults with GH deﬁ-
ciency (GHD) receiving long-term growth hormone (GH)
replacement therapy is correlated with changes in Patient
Reported Outcomes and health care consumption.
METHODS: Data were analysed from 196 Swedish
hypopituitary adults with GHD who had received 2 years
of GH replacement therapy (mean dose, 0.36mg/day). All
patients (95 men, 101 women; mean age at baseline, 
51.1 years; range, 27–71 years; were included in KIMS
(Pharmacia International Metabolic Database)—a large
pharmacoepidemiological survey of adults with GHD.
One hundred nineteen (62%) were in full or part-time
work, and 29 (15%) had taken early retirement or were
receiving a sick beneﬁt. QoL was assessed using
AGHDA—a patient-need based, disease-speciﬁc ques-
tionnaire. Patient Reported Outcomes as general well-
being, level and satisfaction with physical activity at
leisure time (measured on a visual analogue scales) as well
as information on the patients’ social situation were
obtained using the KIMS Patient Life Situation Form.
Days of sick-leave, doctor’s visits and hospital visits were
recorded as a measure of healthcare resource usage.
Patients were divided into four subgroups depending on
the level of improvement in QoL 1) No or deterioration
QoL (n = 52); 2) Moderate (n = 44); 3) Essential (n = 37);
and 4) Excellent (n = 39). Statistical analysis was done
with linear and logistic regression. Adjustments were
done for age and sex. RESULTS: Increased level and sat-
isfaction of physical activity as well as well being were
signiﬁcantly associated with improvements in QoL (p <
0.003). Although healthcare consumption decreased sig-
niﬁcantly during treatment, any clear association with
improvements in QoL was not found. CONCLUSIONS:
The improved QoL in GH-replaced hypopituitary adults
with GHD is signiﬁcantly related to their change in
general well-being and leisure-time activity, whereas the
change in healthcare consumption does not show the
same pattern.
